Overview

* Amicus Q3 2025 revenue grows 17% yr/yr, beating analyst expectations

* Company achieves GAAP net income of $17 mln, reversing a loss from last year

* Cash position increased by $33 mln in Q3 2025

Outlook

* Amicus anticipates 2025 total revenue growth of 15% to 22%

* Company expects Pombiliti + Opfolda revenue growth of 50% to 65% in 2025

* Amicus projects positive GAAP net income in H2 2025

Result Drivers

* GALAFOLD SALES - Galafold sales increased 15% yr/yr, driven by new patient starts and strong compliance

* POMBILITI + OPFOLDA DEMAND - Sales for Pombiliti + Opfolda rose 45% yr/yr due to high demand and new launch countries

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $169 mln $165.70

Revenue mln (9

Analysts

)

Q3 EPS $0.06

Q3 Net $17 mln

Income

Q3 $95.40

Adjusted mln

Operatin

g

Expenses

Q3 $115.30

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Amicus Therapeutics Inc ( FOLD ) is $15.50, about 42.8% above its November 3 closing price of $8.86

* The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)